Earnings Call · Q4 FY2024·2025-03-06

Q4 24EPS -50.00%·Rev n/aQ3 24EPS +25.00%·Rev n/aQ2 24EPS -11.11%·Rev n/aQ1 24EPS -27.27%·Rev n/a⚠ consensus missing

Xeris Biopharma Holdings, Inc. XERS

Allison Wey — Investor Relations

John Shannon — Chief Executive Officer

Steve Pieper — Chief Financial Officer

+9.5%1d on move date+11.3% vs SPY3d+21.8%5d+21.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more XERS calls or request research access.

More XERS calls Browse calls Request research access